Ryon Graf, PhD

Biomedical scientist & ocean lover. Into diagnostics, biostatistics, & outcomes-based evidence. Employer: @FoundationATCG Opinions: my own. RT≠endorsement.

[Paolo Tarantino @PTarantinoMD]

The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! https://t.co/XozXKro2sx

[Todd 〽️ Morgan, MD @wandering_gu]

🚨 New pub: real-world PARP-I response in mCRPC according to DDR alteration status.

Huge credit to 💫 @UMichUrology chief resident (and future @StanfordUrology @SUO_YUO fellow) @TrinerDaniel and the amazing @RyonGraf for all their work on this.

[Bruna Pellini, MD @BrunaPellini]

🚨Happy to share our exciting #ctDNA monitoring research in metastatic NSCLC hot off the press @CCR_AACR 👇https://t.co/c5asgRzgSo @MoffittNews

[Foundation Medicine @FoundationATCG]

In a letter to @CellPressNews' Cancer Cell, our scientists share new research demonstrating a consistent association between high tumor mutational burden (TMB-H) & outcomes on immune checkpoint inhibitors in patients of European, African & Asian ancestry: https://t.co/cNAJlxDdA5

[Todd 〽️ Morgan, MD @wandering_gu]

OS data from PROPEL (Olaparib + Abi) in 1st line mCRPC. 7 mo median OS benefit (p=0.054). But really driven by HRRm subgroup, right? #GU23

[Arun Azad @AzadOncology]

@Ecastromarcos @ASCO #GU23 discussing Talapro-2 & Triton-3 abstracts. Ongoing Qs/challenges:

1. Where will PARPi best fit ? 1L mCRPC? 2L mCRPC? mHSPC?
2. Which pts? BRCA? All-comers?
3. Managing toxicities eg anemia
4. Overcoming resistance eg reversion mutations

[Ryon Graf, PhD @RyonGraf]

@tompowles1 Would like folks to consider MSI and/or TMB, prevalence of positive patients not high but we saw favorable enrichment for benefit of ICI vs. taxane in standard practice settings comparing similar patients @neerajaiims https://t.co/DIifOk4Tvj

[Todd 〽️ Morgan, MD @wandering_gu]

Beautiful summary of mCRPC treatment options with recommended algorithms by @Silke_Gillessen #GU23

[Rana McKay, MD, FASCO @DrRanaMcKay]

Amazing data presented from Talapro-2 by @neerajaiims on the heals of Propel and Magnitude providing future support of PARPi + ARSI. Trials not powered for OS so leaves some open questions.@ASCO #GU23

[Elizabeth Plimack MD @ERPlimackMD]

Surprised to hear such emphatic support of PFS wout OS benefit for PARPi in #prostatecancer when 1 in 4 on PARPi require one or more blood transfusions. Not sure that's a fair ask of @reccross or sustainable at a public health level #GU23 Appreciate @Ecastromarcos counterpoint

[Tom Powles @tompowles1]

Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed rucaparib alone ⬆️ rPFS, particularly in BRCAs. ATM fails to enrich again. OS not +ve yet in either. The biomarker is important for PARPi in CRPC IMO #ASCOGU23

[Shilpa Gupta @shilpaonc]

@Ecastromarcos delivers an elegant &
thoughtful discussion of TALAPRO2 @neerajaiims and TRITON3 @AlanBryce9
We need to understand benefit, ideally need OS benefit before using in HRR beg mCRPC pts, Toxicity can be an issue. #GU23 @ASCO

[Todd 〽️ Morgan, MD @wandering_gu]

Important take home slide from @Ecastromarcos on PARPi role in mCRPC.

BRCA>HRRm>all comers>non-HRRm

#GU23

[JCO Precision Oncology @JCOPO_ASCO]

👀 Check out what’s popular this week in #JCOPO:

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 👉 https://t.co/I4YrGmmyoQ @HatimHusainMD @geoff_oxnard #ctDNA #lcsm

[Ryon Graf, PhD @RyonGraf]

@wandering_gu @ChapinMD @laherrel @AFeldmanMD @theusinghal @gr8straj @PCFnews @charlesryanmd Glad you were able to make it out!

[NatureRevClinOncol @NatRevClinOncol]

Study shows that plasma cfDNA tumour fraction is a pragmatic, independent prognostic biomarker across across pts with mCRPC, mBC, advanced-stage NSCLC and mCRC, with the potential to guide clinical conversations around expected treatment outcomes: https://t.co/weTR5BbwhP

[Annals of Oncology @Annals_Oncology]

This article in Annals of Oncology reports on the prognostic value of ctDNA fraction across different tumor types using real-world data from a de-identified clinico-genomic database

https://t.co/BOIWqEJ7f3

@RyonGraf @ReichertMedOnc @geoff_oxnard @wandering_gu @StoverLab

[Sid Lipsey @sidlipsey]

Loving John Smoltz’s on-air hat tip to the late Tony Gwynn. I knew Gwynn did well against that Braves Hall of Fame ‘90s rotation, but I had no idea the numbers were this ridiculous. He was the best. RIP. #Padres

[Daniel Stover, MD, FASCO @StoverLab]

Great collab evaluating hypothesis that ctDNA tumor fraction may be prognostic across cancers.

Full 🧵to follow!

What a team! Z Reichert @wandering_gu @UMRogelCancer, E. Castellanos et al @flatironhealth, @geoff_oxnard @RyonGraf @FoundationATCG @OSUCCC_James

h/t @PTarantinoMD!

[Ryon Graf, PhD @RyonGraf]

@shilpaonc @GUONCGarciaJA @neerajaiims @umangtalking @OncLiveSOSS @MosheOrnsteinMD @ChrisWeeMD @DrOmarMian @EAntonarakis Thank you for letting us know! Great to see it being talked about!